Overview

Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects with primary insomnia.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Casopitant